The stock, sold at an average price of 5.97 levs apiece, represents 0.027% of Sopharma’s equity capital, the company said in a bourse filing.
The own shares held by Sopharma following the deal amount to 14,155,298, equal to 7.9% of the company's equity capital.
Last August, Sopharma's shareholders endorsed a proposal for a share repurchase programme, which would run for up to 18 months and target up to 3% of the company's equity capital per year.
As of 1532 CEST on Monday, shares in Sopharma traded flat at 5.96 levs on the Bulgarian Stock Exchange.
(1 euro = 1.95583 levs)